Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision

Size: px
Start display at page:

Download "Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision"

Transcription

1 Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision Christopher J. Miller, MD Director of Penn Dermatology Oncology Center Associate Professor of Dermatology

2 I have no conflicts of interest or relevant ties with industry.

3 We are not going to talk about well-defined trunk and proximal extremity melanomas Stage IA melanoma 0.3 mm No ulceration No mitoses

4 Consensus guidelines provide clear surgical treatment recommendations for T&E melanomas

5 We re going to talk about melanomas that challenge consensus guidelines Tis/ Stage 0

6

7 Excision with 0.6 mm margin Immediate reconstruction

8 Upstaged from MIS to IIA Positive margins 1.62 mm, 1 mit/mm2, no ulceration T2b/Stage IIA *Upstaged to SLNB candidacy

9

10 P E N N D E R M ATO L O G Y O N C O L O G Y C E N T E R P I G M E N T E D L E S I O N C L I N I C M O H S A N D R E C O N S T R U C T I V E S U R G E R Y C L I N I C H I G H - R I S K S K I N C A N C E R C L I N I C F O R O R G A N T R A N S P L A N T A N D I M M U N O - S U P P R E S S E D P A T I E N T S R A R E & I N H E R I T E D S K I N C A N C E R C L I N I C

11 Specialty-site melanomas Rule of 10s Head and neck, hands and feet, genitals, pretibial leg 10+% 10x Upstaging Positive excision margins Local recurrence Complex reconstruction

12 Challenge #1 Upstaging from partial preoperative biopsies

13 57 yo woman How would you biopsy? Diagnosis: Melanoma, 4.3 mm

14

15 46 yo woman. How would you biopsy? Diagnosis: Lentigo maligna

16 Partial preoperative biopsies are often a practical necessity Physicians employ a wide variety of biopsy techniques for melanoma Excision Punch Shave Incision Curettage Tadiparthi S et al. Ann R Coll Surg Engl 2008;90:

17 PennDOC Data (Etzkorn J., Miller CJ et al. manuscript in progress) 1345 melanomas treated with conventional wide local excision at Penn between Age, y Range Mean Median Sex Male Female Diagnostic biopsy T stage TIS T1A T1B T2A T2B T3A T3B T4A T4B Location Trunk and proximal extremity Pretibial leg Head and neck Hands and feet Genitals Total Number of Biopsies Range Mean Median Totals % (775/1345) 42.4% (570/1345) 34.1% (458/1345) 36.7% (493/1345) 12.8% (172/1345) 7.2% (97/1345) 1.9% (25/1345) 3.4% (46/1345) 2.2% (29/1345) 0.9% (12/1345) 1.0% (13/1345) 79.3% (1067/1345) 1.9% (26/1345) 15.4% (207/1345) 3.0% (41/1345) 0.3% (4/1345) Stages and locations reflect populationbased data

18 Rates of upstaging of melanoma Overall 3.9% (52/1332) Head, neck, hands, feet, genitals, pretibial leg 12% (32/277) Trunk and proximal extremities 1.8% (19/1055) Etzkorn JR, Miller CJ et al. Frequency of and risk factors for tumor upstaging after WLE of primary cutaneous melanoma. JAAD Under revision

19 Anatomic location is most powerful predictor of upstaging Risk factor Anatomic location on head, neck, hands, feet, genitals, or pretibial leg Extension of melanoma to base of biopsy specimen Odds Ratio (multivariate analysis with step-wise regression) P-value 7.06 < <0.001 Multiple preoperative biopsies Older age 1.03 (per year) Non-LM histologic subtype % (32/272) risk of upstaging at specialty sites (versus 1.8% [19/1055] on T&E) Etzkorn JR, Miller CJ et al. Frequency of and risk factors for tumor upstaging after WLE of primary cutaneous melanoma. JAAD Under revision

20 Upstaging may affect surgical management Chance that upstaged tumor will change margin recommendations Chance that upstaged tumor will qualify for SLNB 62% (32/52) 27% (14/52)

21 Challenge #1: Upstaging due to partial preoperative biopsies Upstaging complicates: Patient counseling Margin determination Sentinel lymph node biopsy Preoperative staging: T1a Melanoma, 0.22 mm Postoperative staging: T2a Melanoma, 1.65 mm Recon delayed for SLNB

22 Challenge #2 Positive margins due to inaccurate clinical and surgical margins

23 Melanoma, 0.30 mm What margin would you excise?

24

25 Inaccurate clinical margins = Inaccurate surgical margins Diagnosis: MIS What margin would you excise?

26 Recommended margins were used in only 67.8% of standard excisions of melanomas on the head neck Insufficient margin of excision (i.e., less than recommended) independently associated with tumor location on the head and neck Specialty of surgeon did not affect compliance with recommended margins Livingstone E et al. European J of Cancer 2011;47:

27 PennDOC Data (Etzkorn J., Miller CJ et al. manuscript in progress) 1345 melanomas treated with conventional wide local excision at Penn between Age, y Range Mean Median Sex Male Female Diagnostic biopsy T stage TIS T1A T1B T2A T2B T3A T3B T4A T4B Location Trunk and proximal extremity Pretibial leg Head and neck Hands and feet Genitals Total Number of Biopsies Range Mean Median Totals % (775/1345) 42.4% (570/1345) 34.1% (458/1345) 36.7% (493/1345) 12.8% (172/1345) 7.2% (97/1345) 1.9% (25/1345) 3.4% (46/1345) 2.2% (29/1345) 0.9% (12/1345) 1.0% (13/1345) 79.3% (1067/1345) 1.9% (26/1345) 15.4% (207/1345) 3.0% (41/1345) 0.3% (4/1345)

28 Rates of positive margins after WLE Overall 4.2% (56/1345) Head, neck, hands, feet, genitals, pretibial leg 11.5% (32/278) Trunk and proximal extremities 2.2% (24/1067) Etzkorn JR, Miller CJ et al. Risk factors for positive or equivocal margins after WLE of 1345 cutaneous melanomas. JAAD Under revision

29 Predictors of positive margins on conventional WLE Risk factor Non-compliance with recommended margins Anatomic location on head, neck, hands, feet, genitals, or pretibial leg Odds Ratio (multivariate analysis with step-wise regression) P-value <0.001 Histologic regression Melanoma in situ Multiple preoperative biopsies 1.92 (per biopsy) Older age (per year) < % (32/278) risk of positive margins at specialty sites (versus 2.2% [24/1067] on T&E)

30 Challenge #3 Local recurrence due to inaccurate pathologic margins

31 Local recurrence of melanoma Head and neck 13% (388/2984) Trunk and extremities 1.7% (144/8400) Historical data from Table IV in Etzkorn JR, Miller CJ et al J Am Acad Dermatol 2015;72:840-50

32 Local recurrence rates are higher for specialty-site MM 1.7% (144/8400) Range: % 13% (388/2984) Range (2.8-28%) Etzkorn JR, Miller CJ et al J Am Acad Dermatol 2015;72:840-50

33 Local recurrence is more common for specialty site melanoma Positive margins complicate: Patient counseling Margin determination Timing of reconstruction Persistent lentigo maligna melanoma in graft Defect after excision of recurrence/persistence

34 Challenge #4 Timing of reconstruction relative to margin determination

35 10x greater likelihood of complex reconstruction for specialty site melanomas Anatomic location Frequency of flap or graft reconstruction Odds Ratio (95% CI) P-value Specialty site 53.7% (275/512) 10.3 ( ) Trunk and proximal extremity 10.1% (8/79) 1 (reference) Etzkorn JR, Miller CJ et al. Dermatol Surg 2016;42:

36 MIS Preoperative Mohs defect

37 Complex reconstruction is 10 times more likely for specialty-site melanomas 4 months postoperative

38 Previously treated melanomas are significantly more likely to require more complex reconstruction Etzkorn JR, Miller CJ et al. Dermatol Surg 2016;42: Linear scar previous surgery 10/11/2011 Final Mohs defect 4 stages

39 People place highest priority on restoring normalcy of specialty sites Borah GL, Rankin MK. Plast Reconstr Surg 2010;125:873

40 Conditions for optimal surgery of melanomas Accurate pathologic staging prior to reconstruction Clear microscopic margins Reconstruction in tumor-free skin

41 JAAD 2015 First 597 melanomas of >1800 cases since 2006 Two outcome measures Accuracy of staging prior to recon: 99.8% (596/597) Local recurrence rate: 0.34% (2/597) average f/u: 2.8 years

42 Combine breadloaf sectioning of central tumor with Mohs margin assessment prior to reconstruction

43 H&E and MART-1 frozens on all sections of debulk and Mohs layer MART-1 Debulk Excision Vertical Sections H&E

44 melanocyte keratinocyte H&E frozen section MART-1 frozen section

45 Mohs surgery video

46 Did we meet the 3 conditions for optimal surgery of melanomas? Accurate pathologic staging prior to reconstruction Clear microscopic margins Reconstruction in tumor-free skin

47 Treatment goal #1: Accurate pathologic staging prior to reconstruction 99.8% accurate (596/597) Breadloaf sectioning of the central tumor prior to reconstruction

48 34/614 (5.5%) patients upstaged AJCC T category 8 97% (33/34) detected by Mohs surgeon prior to reconstruction

49 23.5% (8/34) upstaged to criteria qualifying for SLNB 3 patient elected to undergo SLNB (1 was positive) Melanoma, 0.22 mm Melanoma, 1.65 mm Recon delayed for SLNB

50 Treatment goal #2: -Clear microscopic margins 100% microscopic margin assessment of the Mohs layer with MART-1 frozen section immunostains

51 Local recurrence rate 0.34% (2/597) (Mean follow time: 2.8 years)

52 Comparison historical rates of local recurrence after conventional surgery % % 10%

53 Estimated local recurrence rate after conventional surgery (historical published data) 2/597 (0.34%) 60/597 (10%) Penn local recurrence rate (published Penn data)

54 Treatment goal #3: -Reconstruction in tumor-free field 100% microscopic margin assessment of the Mohs layer with MART-1 frozen section immunostains

55 Complex reconstruction in tumor-free skin >55% of head and neck melanomas were repaired with either a flap or graft Chart Title Flap Flap and graft Graft Linear Linear + graft Linear + second intent Second intent 0 Referred out Head and neck Trunk and extremity

56 Specialty-site melanomas Rule of 10s Head and neck, hands and feet, genitals, pretibial leg 10+% 10x Upstaging Positive excision margins Local recurrence Complex reconstruction

57 Combine breadloaf sectioning of central tumor with Mohs margin assessment prior to reconstruction

58 Mohs Surgery for Melanoma at Penn Dermatology Oncology Center

Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy

Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,

More information

Dr. Brent Doolan, BSc MBBS MPH

Dr. Brent Doolan, BSc MBBS MPH Impact of partial biopsies on the need for complete excisional surgery in the management of cutaneous melanomas: A multi-centre review Dr. Brent Doolan, BSc MBBS MPH Peter MacCallum Cancer Centre, Melbourne

More information

Melanoma Update: 8th Edition of AJCC Staging System

Melanoma Update: 8th Edition of AJCC Staging System Melanoma Update: 8th Edition of AJCC Staging System Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY None

More information

Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)

Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma

More information

Melanoma Quality Reporting

Melanoma Quality Reporting Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,

More information

What are the new AJCC Staging System changes, and how will they affect my patients?

What are the new AJCC Staging System changes, and how will they affect my patients? What are the new AJCC Staging System changes, and how will they affect my patients? Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine University of Pennsylvania

More information

Primary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type

Primary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type Primary Cutaneous Melanoma Pathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth DD MM YYYY Sex Male Female

More information

Technicians & Nurses Program

Technicians & Nurses Program ASCRS ASOA Symposium & Congress Technicians & Nurses Program May 6-10, 2016 New Orleans Evaluation and Treatment of Eyelid Malignancies Richard C. Allen MD PhD FACS Professor Section of Ophthalmology Dept.

More information

Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD

Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD Disclosure Statement Update on Melanoma Are You Following the Latest Guidelines of Care? I, Jerry D. Brewer, MD, do

More information

Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy

Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)

More information

WHAT DOES THE PATHOLOGY REPORT MEAN?

WHAT DOES THE PATHOLOGY REPORT MEAN? Melanoma WHAT IS MELANOMA? Melanoma is a type of cancer that affects cells called melanocytes. These cells are found mainly in skin but also in the lining of other areas such as nose and rectum, and also

More information

Melanoma Extirpation with Immediate Reconstruction: The Oncologic Safety and Cost Savings of Single-Stage Treatment.

Melanoma Extirpation with Immediate Reconstruction: The Oncologic Safety and Cost Savings of Single-Stage Treatment. RECONSTRUCTIVE Melanoma Extirpation with Immediate Reconstruction: The Oncologic Safety and Cost Savings of Single-Stage Treatment Irena Karanetz, M.D. Sharon Stanley, M.D. Denis Knobel, M.D. Benjamin

More information

Proposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL

Proposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL Proposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL on behalf of Dr Louise Lansbury, Prof Fiona Bath-Hextall Nottingham Centre for Evidence Based

More information

Disclosures. SLNB for Melanoma 25/02/2014 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION

Disclosures. SLNB for Melanoma 25/02/2014 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION 8 th Canadian Melanoma Conference February 22, 2014 Rimrock Resort Hotel, Banff, Alberta SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION Christopher Bichakjian,

More information

1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.

1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter. Skin Cancer follow up guidelines If NEW serious diagnosis given: 1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter. 2. Free prescription information details. 3.

More information

Skin Cancer 101: Diagnosis and Management of the Most Common Cancer

Skin Cancer 101: Diagnosis and Management of the Most Common Cancer Skin Cancer 101: Diagnosis and Management of the Most Common Cancer Sarah Patton, PA-C, MSHS Skin Surgery Center www.skinsurgerycenter.com Seattle/Bellevue, WA Skin cancer Skin cancer is by far the most

More information

Limitations of nonsurgical treatment modalities. Nonsurgical Treatments (Table V) 1/31/2018

Limitations of nonsurgical treatment modalities. Nonsurgical Treatments (Table V) 1/31/2018 DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY James M. Grichnik M.D. Ph.D. Alternative Therapies James M Grichnik MD PhD Director, Scully-Welsh Cancer Center Indian River Medical Center grichnik@irmc.cc

More information

3/19/17. Disclosure. None

3/19/17. Disclosure. None Disclosure David M Ozog MD, Chairman Department of Dermatology Mohs and Dermatologic Surgery, Henry Ford Hospital Detroit, Michigan None 24 Senior Staff Physicians 18 Residents/3 Research Fellows Basic

More information

Melanoma. Kaushik Mukherjee MD A. Scott Pearson MD

Melanoma. Kaushik Mukherjee MD A. Scott Pearson MD Melanoma Kaushik Mukherjee MD A. Scott Pearson MD Disclosures You still have to study Not all inclusive No Western blots Extensive use of Google Image Search and Sabiston Melanoma Basics 8 th most common

More information

Lentigo Maligna: Striking a Balance With the Risk-Benefit Ratio. Glen M. Bowen, MD Huntsman Cancer Institute University of Utah

Lentigo Maligna: Striking a Balance With the Risk-Benefit Ratio. Glen M. Bowen, MD Huntsman Cancer Institute University of Utah Lentigo Maligna: Striking a Balance With the Risk-Benefit Ratio Glen M. Bowen, MD Huntsman Cancer Institute University of Utah I. Objectives: a. Review the terminology of LM/LMM b. Understand the relative

More information

Melanoma and Dermoscopy. Disclosure Statement: ABCDE's of melanoma. Co-President, Usatine Media

Melanoma and Dermoscopy. Disclosure Statement: ABCDE's of melanoma. Co-President, Usatine Media Melanoma and Dermoscopy Richard P. Usatine, MD, FAAFP Professor, Family and Community Medicine Professor, Dermatology and Cutaneous Surgery Medical Director, University Skin Clinic University of Texas

More information

Practical Tips for Caring for Melanoma Patients

Practical Tips for Caring for Melanoma Patients Practical Tips for Caring for Melanoma Patients Caroline C. Kim, MD, Director Assistant Professor, Department of Dermatology Harvard Medical School Director, Pigmented Lesion Clinic Associate Director,

More information

Clinical Case Conference Melanoma

Clinical Case Conference Melanoma Clinical Case Conference Melanoma Epidemiology ~60,000 cases and 8,000 deaths per year in US Caucasian:African American = 10:1 15% arise from existing nevi 91% are cutaneous 15% are LN+ at presentation

More information

Identifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018

Identifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018 Identifying Skin Cancer Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018 American Cancer Society web site Skin Cancer Melanoma Non-Melanoma

More information

6/22/2015. Original Paradigm. Correlating Histology and Molecular Findings in Melanocytic Neoplasms

6/22/2015. Original Paradigm. Correlating Histology and Molecular Findings in Melanocytic Neoplasms 6 Correlating Histology and Molecular Findings in Melanocytic Neoplasms Pedram Gerami MD, Associate Professor of Dermatology and Pediatrics at Northwestern University Disclosures: I have been a consultant

More information

Index. Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, Anorectal melanoma RT for, 1035

Index. Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, Anorectal melanoma RT for, 1035 Index Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, 947 948 Anorectal melanoma RT for, 1035 B Bacille Calmette-Guerin (BCG) in melanoma, 1008 BCG. See Bacille

More information

Controversies and Questions in the Surgical Treatment of Melanoma

Controversies and Questions in the Surgical Treatment of Melanoma Controversies and Questions in the Surgical Treatment of Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Division of Endocrine and Oncologic Surgery University of Pennsylvania School

More information

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior

More information

Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases

Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Faruk Tas, Sidika Kurul, Hakan Camlica and Erkan Topuz Institute of Oncology, Istanbul University, Istanbul, Turkey Received

More information

Desmoplastic Melanoma: Clinical Behavior and Management Implications

Desmoplastic Melanoma: Clinical Behavior and Management Implications Desmoplastic Melanoma: Clinical Behavior and Management Implications Collier S. Pace, MD, a Jyoti P. Kapil, MD, b Luke G. Wolfe, MS, c Brian J. Kaplan, MD, c and James P. Neifeld, MD c a Division of Plastic

More information

Melanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division

Melanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Melanoma Surgery Update 2018 James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Surgery for Melanoma Mainstay of treatment for potentially

More information

Pearls for Keeping it Simple in Cutaneous Reconstruction

Pearls for Keeping it Simple in Cutaneous Reconstruction Pearls for Keeping it Simple in Cutaneous Reconstruction Jerry D. Brewer, MD, MS, FAAD brewer.jerry@mayo.edu Professor of Dermatology Division of Dermatologic Surgery Department of Dermatology Mayo Clinic

More information

Clinico-pathological Features of Patients with Melanoma and Positive Sentinel Lymph Node Biopsy: A Single Institution Experience

Clinico-pathological Features of Patients with Melanoma and Positive Sentinel Lymph Node Biopsy: A Single Institution Experience 2015;23(2):122-129 CLINICAL ARTICLE Clinico-pathological Features of Patients with Melanoma and Positive Sentinel Lymph Node Biopsy: A Single Institution Experience Damir Homolak 1, Mirna Šitum 2,3, Hrvoje

More information

MING H. JIH, MD,PHD, PAUL M. FRIEDMAN, MD,LEONARD H. GOLDBERG, MD,AND ARASH KIMYAI-ASADI, MD. Methods Phase I: Retrospective (Group 1)

MING H. JIH, MD,PHD, PAUL M. FRIEDMAN, MD,LEONARD H. GOLDBERG, MD,AND ARASH KIMYAI-ASADI, MD. Methods Phase I: Retrospective (Group 1) Curettage prior to Mohs Micrographic Surgery for Previously Biopsied Nonmelanoma Skin Cancers: What Are We Curetting? Retrospective, Prospective, and Comparative Study MING H. JIH, MD,PHD, PAUL M. FRIEDMAN,

More information

AJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna

AJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna AJCC 8 Implementation January 1, 2018 Melanoma of the Skin Suraj Venna Personalized Medicine AJCC 8 th Edition This Time It s Personal Traditional AJCC (TNM) population-based analyses of large databases

More information

Talk to Your Doctor. Fact Sheet

Talk to Your Doctor. Fact Sheet Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent

More information

Epithelial Cancer- NMSC & Melanoma

Epithelial Cancer- NMSC & Melanoma Epithelial Cancer- NMSC & Melanoma David Chin MB, BCh, BAO, LRCP, LRCS (Ireland) MCh(MD), PhD (UQ), FRCS, FRACS (Plast) Plastic & Reconstructive Surgeon Visiting Scientist Melanoma Genomic Group & Drug

More information

Evidence for Mohs surgery

Evidence for Mohs surgery Evidence for Mohs surgery Simone van der Geer Dermatologist, Mohs surgeon Secretary of the ESMS Excision Mohs 3-5 mm clinical margin 0,1% margin control (Abide, The meaning of surgical margins. Plast Reconstr

More information

Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology

Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Outline Germline testing CDKN2A BRCA2 BAP1 Somatic testing Gene expression profiling (GEP) BRAF Germline vs Somatic testing

More information

INTRODUCTION. Abbreviations used: ALM: acral lentiginous melanoma LM: lentigo maligna MM: melanoma MMS: Mohs micrographic surgery SS: staged surgery

INTRODUCTION. Abbreviations used: ALM: acral lentiginous melanoma LM: lentigo maligna MM: melanoma MMS: Mohs micrographic surgery SS: staged surgery The spaghetti technique : An alternative to Mohs surgery or staged surgery for problematic lentiginous melanoma (lentigo maligna and acral lentiginous melanoma) Caroline Gaudy-Marqueste, MD, PhD, a Anne-Sophie

More information

SKIN CANCER. Most common cancer diagnosis 40% of all cancers

SKIN CANCER. Most common cancer diagnosis 40% of all cancers SKIN CANCER Most common cancer diagnosis 40% of all cancers OBJECTIVES Review common and uncommon cancers of the skin. Special emphasis on melanoma and dysplastic nevus Review pathology/tnm/staging, which

More information

Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective

Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Giorgos C. Karakousis, M.D. Associate Professor of Surgery Hospital of the University of Pennsylvania Disclosures

More information

Skin Cancer of the Nose: Common and Uncommon

Skin Cancer of the Nose: Common and Uncommon Skin Cancer of the Nose: Common and Uncommon Mark Russell, M.D. Associate Professor of Dermatology, Otolaryngology, and Pathology University of Virginia Objectives Review clinical presentations of select

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Gene Expression Profiling for Cutaneous Melanoma File Name: Origination: Last CAP Review: Next CAP Review: Last Review: gene_expression_profiling_for_cutaneous_melanoma 5/2018

More information

Policy #: 127 Latest Review Date: June 2011

Policy #: 127 Latest Review Date: June 2011 Name of Policy: Mohs Micrographic Surgery Policy #: 127 Latest Review Date: June 2011 Category: Surgery Policy Grade: Active Policy but no longer scheduled for regular literature reviews and updates. Background/Definitions:

More information

Dermatology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI Memorial

Dermatology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI Memorial Dermatology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI Memorial Cutaneous Oncology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI

More information

Interesting Case Series. Aggressive Tumor of the Midface

Interesting Case Series. Aggressive Tumor of the Midface Interesting Case Series Aggressive Tumor of the Midface Adrian Frunza, MD, Dragos Slavescu, MD, and Ioan Lascar, MD, PhD Bucharest Emergency Clinical Hospital, Bucharest University School of Medicine,

More information

Springer Healthcare. Staging and Diagnosing Cutaneous Melanoma. Concise Reference. Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone

Springer Healthcare. Staging and Diagnosing Cutaneous Melanoma. Concise Reference. Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone Concise Reference Staging and Diagnosing Cutaneous Melanoma Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone Extracted from Handbook of Cutaneous Melanoma: A Guide to Diagnosis and Treatment Published

More information

ORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma

ORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma ORIGINAL ARTICLE Clinical Node-Negative Thick Melanoma George I. Salti, MD; Ashwin Kansagra, MD; Michael A. Warso, MD; Salve G. Ronan, MD ; Tapas K. Das Gupta, MD, PhD, DSc Background: Patients with T4

More information

Toby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma

Toby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma Distinguishing Pigmented Skin Lesions and Melanoma Toby Maurer, MD University of California, San Francisco Epidemiology of Melanoma Lifetime risk of an American developing melanoma 1935: 1 in 1500 1980:

More information

Contralateral Prophylactic Mastectomy with Immediate Reconstruction: Added Benefits, Added Risks

Contralateral Prophylactic Mastectomy with Immediate Reconstruction: Added Benefits, Added Risks Contralateral Prophylactic Mastectomy with Immediate Reconstruction: Added Benefits, Added Risks Grant W. Carlson Wadley R. Glenn Professor of Surgery Divisions of Plastic Surgery & Surgical Oncology Emory

More information

Diagnosis of Lentigo Maligna Melanoma. Steven Q. Wang, M.D. Memorial Sloan-Kettering Cancer Center Basking Ridge, NJ

Diagnosis of Lentigo Maligna Melanoma. Steven Q. Wang, M.D. Memorial Sloan-Kettering Cancer Center Basking Ridge, NJ Diagnosis of Lentigo Maligna Melanoma Steven Q. Wang, M.D. Memorial Sloan-Kettering Cancer Center Basking Ridge, NJ Conflict of Interest: None Topics Epidemiology and Natural History Clinical and Histologic

More information

Molecular Methods in the Diagnosis and Prognostication of Melanoma: Pros & Cons

Molecular Methods in the Diagnosis and Prognostication of Melanoma: Pros & Cons Molecular Methods in the Diagnosis and Prognostication of Melanoma: Pros & Cons Ben J. Friedman, MD Senior Staff Physician Department of Dermatology Department of Pathology and Laboratory Medicine Henry

More information

Basic Standards for Fellowship Training in Mohs Micrographic Surgery

Basic Standards for Fellowship Training in Mohs Micrographic Surgery Basic Standards for Fellowship Training in Mohs Micrographic Surgery American Osteopathic Association and American Osteopathic College of Dermatologists September, 1992 BOT/93 BOT 7/2011, Eff. 7/2012 Basic

More information

Nodal Treatment in Melanoma: Snow to MSLT-II

Nodal Treatment in Melanoma: Snow to MSLT-II Nodal Treatment in Melanoma: Snow to MSLT-II Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Program Director, JWCI Complex General Surgical Oncology Fellowship Director,

More information

Melanoma. Consultation on draft guideline - stakeholder comments. Comments to be submitted before 5pm on Friday 13 March 2015

Melanoma. Consultation on draft guideline - stakeholder comments. Comments to be submitted before 5pm on Friday 13 March 2015 Please note: Please fill in both the stakeholder organisation and name of commentator fields. We cannot accept forms with attachments such as research articles, letters or leaflets. Stakeholder organisation(s)

More information

Cancer of the Oral Cavity

Cancer of the Oral Cavity The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology Cancer of the Oral Cavity Ashok Shaha Principals of Management of Oral Cancer A)

More information

Cutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D.

Cutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D. Cutaneous Malignancies: A Primer Marissa Heller, M.D. Associate Director of Dermatologic Surgery Department of Dermatology Beth Israel Deaconess Medical Center December 10, 2016 Skin Cancer Non-melanoma

More information

Research Article Melanoma in Buckinghamshire: Data from the Inception of the Skin Cancer Multidisciplinary Team

Research Article Melanoma in Buckinghamshire: Data from the Inception of the Skin Cancer Multidisciplinary Team Skin Cancer Volume 2013, Article ID 843282, 6 pages http://dx.doi.org/10.1155/2013/843282 Research Article Melanoma in Buckinghamshire: Data from the Inception of the Skin Cancer Multidisciplinary Team

More information

NAACCR Webinar Series 1

NAACCR Webinar Series 1 Collecting Cancer Data: Melanoma 2013 2014 NAACCR Webinar Series April 3, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching

More information

A superficial radiotherapy B single pass curettage C excision with 2 mm margins D excision with 5 mm margins E Mohs micrographic surgery.

A superficial radiotherapy B single pass curettage C excision with 2 mm margins D excision with 5 mm margins E Mohs micrographic surgery. 1- A 63-year-old woman presents with a non-healing lesion on her right temple that has been present for over two years. On examination there is a 6 mm well defined lesion with central ulceration, telangiectasia

More information

Skin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012

Skin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012 Skin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012 Case Presentation 57 yo man with 3 month hx of a nonhealing < 1 cm right

More information

Radionuclide detection of sentinel lymph node

Radionuclide detection of sentinel lymph node Radionuclide detection of sentinel lymph node Sophia I. Koukouraki Assoc. Professor Department of Nuclear Medicine Medicine School, University of Crete 1 BACKGROUND The prognosis of malignant disease is

More information

Topics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes:

Topics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes: Topics for Discussion What is a sentinel lymph node (SLN)? Utility of sentinel lymph biopsies: therapeutic or staging? Current Treatment of Cutaneous Melanoma Carlos Corvera, M.D. Associate Professor of

More information

Rebecca Vogel, PGY-4 March 5, 2012

Rebecca Vogel, PGY-4 March 5, 2012 Rebecca Vogel, PGY-4 March 5, 2012 Historical Perspective Changes In The Staging System Studies That Started The Talk Where We Go From Here Cutaneous melanoma has become an increasingly growing problem,

More information

Skin Cancer. 5 Warning Signs. American Osteopathic College of Occupational and Preventive Medicine OMED 2012, San Diego, Monday, October 8, 2012 C-1

Skin Cancer. 5 Warning Signs. American Osteopathic College of Occupational and Preventive Medicine OMED 2012, San Diego, Monday, October 8, 2012 C-1 Skin Cancer AMERICAN OSTEOPATHIC COLLEGE OF OCCUPATIONAL & PREVENTIVE MEDICINE OMED 2012 October 8, 2012 E. Robert Wanat II, D.O., M.P.H. Learning Objectives: Identify the 3 Basic Types of Skin Cancer

More information

Chapter 11 Worksheet Code It

Chapter 11 Worksheet Code It Class: Date: Chapter 11 Worksheet 3 2 1 Code It True/False Indicate whether the statement is true or false. 1. Surgical destruction is considered part of the surgical procedure description. 2. Prepping

More information

> 6000 Mutations in Melanoma. Tests That Cay Be Employed. FISH for Additions/Deletions. Comparative Genomic Hybridization

> 6000 Mutations in Melanoma. Tests That Cay Be Employed. FISH for Additions/Deletions. Comparative Genomic Hybridization Winter Clinical 2017: The Assessment and Diagnosis of Melanoma Whitney A. High, MD, JD, MEng Associate Professor, Dermatology & Pathology Director of Dermatopathology (Dermatology) University of Colorado

More information

Skin lesions suspicious for melanoma: New Zealand excision margin guidelines in practice

Skin lesions suspicious for melanoma: New Zealand excision margin guidelines in practice Skin lesions suspicious for melanoma: excision margin guidelines in practice Tess Brian MBBS; 1 Michael B. Jameson MBChB, FRACP, FRCP, PhD 2,3 1 Department of Plastic and Reconstructive Surgery, Waikato

More information

For additional information on meeting the criteria for Mohs, see Appendix 2.

For additional information on meeting the criteria for Mohs, see Appendix 2. Position Statement on Appropriate Uses of Paraffin Sections in Association (Approved by the Board of Directors: August 1, 2011; Revised November 5, 2011; Revised August 9, 2014) According to AMA/CPT, Mohs

More information

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our

More information

You Are Going to Cut How Much Skin? Locoregional Surgical Treatment. Justin Rivard MD, MSc, FRCSC September 21, 2018

You Are Going to Cut How Much Skin? Locoregional Surgical Treatment. Justin Rivard MD, MSc, FRCSC September 21, 2018 You Are Going to Cut How Much Skin? Locoregional Surgical Treatment Justin Rivard MD, MSc, FRCSC September 21, 2018 Presenter Disclosure Faculty/Speaker: Justin Rivard Relationships with financial sponsors:

More information

Aesthetic surgery techniques after excision of dermatofibrosarcoma protuberans: a case report

Aesthetic surgery techniques after excision of dermatofibrosarcoma protuberans: a case report British Journal of Plastic Surgery (2005) 58, 556 560 CASE REPORT Aesthetic surgery techniques after excision of dermatofibrosarcoma protuberans: a case report G. Dagregorio a, *, V. Darsonval b a Department

More information

David B. Troxel, MD. Common Medicolegal Situations: Misdiagnosis of Melanoma

David B. Troxel, MD. Common Medicolegal Situations: Misdiagnosis of Melanoma Common Medicolegal Situations: Misdiagnosis of Melanoma David B. Troxel, MD Medical Director, The Doctors Company, Napa, California Clinical Professor Emeritus, University of California at Berkeley Past

More information

Oncology and surgery. Dra. Irene Palacios. Clínica Universidad de Navarra

Oncology and surgery. Dra. Irene Palacios. Clínica Universidad de Navarra Oncology and surgery Dra. Irene Palacios. Clínica Universidad de Navarra HOW TO MANAGE HIGH RISK SCC Yaouhi Gloria Xu Anokhi Jambusaria-Pahlajani HOW TO STAGE SCC Problem with tumor depth Often not posible

More information

47. Melanoma of the Skin

47. Melanoma of the Skin 1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting

More information

Epidemiology. Objectives 8/28/2017

Epidemiology. Objectives 8/28/2017 Case based Discussion of Head and Neck Melanoma: Review of Epidemiology, Risk Factors, Identification, Treatments and Prevention Jacqueline M. Doucette MS FNP-C Objectives Define and identify melanoma

More information

Mohs surgery for the nail unit

Mohs surgery for the nail unit Mohs surgery for the nail unit olivier.cogrel@chu-bordeaux.fr Dermatologic surgery, Mohs surgery and lasers unit CHU Bordeaux, France Squamous cell carcinoma +++ Acral lentiginous melanoma Lichte et al.

More information

Glenn D. Goldman, MD. Fletcher Allen Health Care. University of Vermont College of Medicine

Glenn D. Goldman, MD. Fletcher Allen Health Care. University of Vermont College of Medicine Glenn D. Goldman, MD Fletcher Allen Health Care University of Vermont College of Medicine Recognize and identify the main types of skin cancer Understand how and why Mohs surgery is utilized for the treatment

More information

Contrast with Australian Guidelines A/Pr Pascale Guitera,

Contrast with Australian Guidelines A/Pr Pascale Guitera, Contrast with Australian Guidelines A/Pr Pascale Guitera, Dermatologist, Sydney University NO CONFLICT OF INTEREST Sydney Melanoma Diagnostic Centre, RPAH 2011 2008 225 pages 16 pages http://www.cancer.org.au/file/healthprofessionals/clinica

More information

Impact of Prognostic Factors

Impact of Prognostic Factors Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,

More information

The Reverse Galeal Hinge Flap: Another Valuable Technique in the Repair of Scalp

The Reverse Galeal Hinge Flap: Another Valuable Technique in the Repair of Scalp TITLE PAGE TITLE: The Reverse Galeal Hinge Flap: Another Valuable Technique in the Repair of Scalp Defects Extending to the Calvarium AUTHORS: Lam, Thomas, BA; Indiana University School of Medicine Miletta,

More information

Toby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma

Toby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma Distinguishing Pigmented Skin Lesions and Melanoma Toby Maurer, MD University of California, San Francisco Epidemiology of Melanoma Lifetime risk of an American developing melanoma 1935: 1 in 1500 1980:

More information

No Benefit to Routine Completion Lymphadenectomy for Sentinel Lymph Node Positive Melanoma

No Benefit to Routine Completion Lymphadenectomy for Sentinel Lymph Node Positive Melanoma No Benefit to Routine Completion Lymphadenectomy for Sentinel Lymph Node Positive Melanoma Michael Lowe, MD Assistant Professor of Surgery Winship Cancer Institute Emory University School of Medicine July

More information

Diagnostics guidance Published: 11 November 2015 nice.org.uk/guidance/dg19

Diagnostics guidance Published: 11 November 2015 nice.org.uk/guidance/dg19 VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions Diagnostics guidance Published: 11 November 2015 nice.org.uk/guidance/dg19 NICE 2018. All rights reserved. Subject to Notice of

More information

Benign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc

Benign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc 1 Benign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc Benign lesions Seborrheic Keratoses: Warty, stuck-on Genetics and birthdays Can start in late

More information

Update on Lymph Node Management in Melanoma

Update on Lymph Node Management in Melanoma Update on Lymph Node Management in Melanoma John T. Vetto MD, FACS Professor of Surgery Division of Surgical Oncology Oregon Health & Science University Portland, Oregon Lymph Nodes in Melanoma Outline

More information

Molecular Enhancement of Sentinel Node Evaluation

Molecular Enhancement of Sentinel Node Evaluation Cochran Illustrations 060104 Molecular Enhancement of Sentinel Node Evaluation Alistair Cochran, MD and Rong Huang MD Departments of Pathology and Laboratory Medicine and Surgery, David Geffen School of

More information

Precision Surgery for Melanoma

Precision Surgery for Melanoma Precision Surgery for Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Perelman School of Medicine at the University of Pennsylvania Background 87,110 cases of melanoma estimated in

More information

The Role of Mohs Micrographic Surgery in Skin Cancer Treatment

The Role of Mohs Micrographic Surgery in Skin Cancer Treatment Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/the-role-of-mohs-micrographic-surgery-in-skincancer-treatment/3643/

More information

Melanoma and Mimickers

Melanoma and Mimickers Melanoma and Mimickers Kara Walton, MD Assistant Professor of Dermatology and Dermatopathology Medical College of Wisconsin Disclosures No relevant financial disclosures 1 Objectives Recognize common benign

More information

Glenn D. Goldman, MD. University of Vermont Medical Center. University of Vermont College of Medicine

Glenn D. Goldman, MD. University of Vermont Medical Center. University of Vermont College of Medicine Glenn D. Goldman, MD University of Vermont Medical Center University of Vermont College of Medicine Recognize and identify the main types of skin cancer and their precursors Identify and understand new

More information

Desmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC

Desmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC R/O BCC Sabine Kohler, M.D. Professor of Pathology and Dermatology Dermatopathology Service Stanford University School of Medicine Clinical Information 74 y.o. man with lesion on left side of neck r/o

More information

Surgery for Melanoma and What s on the Horizon

Surgery for Melanoma and What s on the Horizon and What s on the Horizon Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Perelman School of Medicine at the University of Pennsylvania Background/Overview 76,870 cases of melanoma estimated

More information

Cancer Council Australia Wiki Guidelines 2017

Cancer Council Australia Wiki Guidelines 2017 WHAT IS THE ROLE OF SEQUENTIAL DIGITAL DERMOSCOPY IMAGING IN MELANOMA DIAGNOSIS? Cancer Council Australia Wiki Guidelines 2017 SHORT-TERM MONITORING 3 months Any change leads to excision Any melanocytic

More information

An Overview of Melanoma. Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center

An Overview of Melanoma. Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center An Overview of Melanoma Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center Melanoma Statistics Median age at presentation 45-55 55 years Incidence: 2003 54,200 cases

More information

The Case FOR Oncoplastic Surgery in Small Breasts. Barbara L. Smith, MD, PhD Massachusetts General Hospital Harvard Medical School Boston, MA USA

The Case FOR Oncoplastic Surgery in Small Breasts. Barbara L. Smith, MD, PhD Massachusetts General Hospital Harvard Medical School Boston, MA USA The Case FOR Oncoplastic Surgery in Small Breasts Barbara L. Smith, MD, PhD Massachusetts General Hospital Harvard Medical School Boston, MA USA Changing issues in breast cancer management Early detection

More information

PATIENT INFORMATION. Mohs Micrographic Surgery. In the Treatment of Skin Cancer

PATIENT INFORMATION. Mohs Micrographic Surgery. In the Treatment of Skin Cancer PATIENT INFORMATION Mohs Micrographic Surgery In the Treatment of Skin Cancer What is Mohs Micrographic Surgery? Mohs micrographic surgery is a specialized, highly effective technique for the removal

More information

Regeneron and Sanofi are financial supporters of The Skin Cancer Foundation and collaborated in the development of this article. US-ONC /2018

Regeneron and Sanofi are financial supporters of The Skin Cancer Foundation and collaborated in the development of this article. US-ONC /2018 A D E E P E R L O O K When detected early, most cases of local cutaneous squamous cell carcinoma are easily treated and usually cured. But when they become more advanced, this second most common form of

More information